AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04285424 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: The fecal collection produced from a single healthy donor, unrelated to the patients
Study NCT02032381 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.
Study NCT03470714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Force Irradiation
Description: For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
Study NCT03470714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Force Irradiation
Description: For the force irradiation, while the subjects perform dominant elbow flexion at an angular velocity of 60°/s for concentric contractions, 30°/s for eccentric contractions, at 90° elbow flexion position for isometric contractions with a maximal effort level, electrical activity of the non-dominant biceps brachii and triceps brachii muscles are recorded.
Study NCT03470714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: For kinesiotaping, the elbow positioned in 30°-45° flexion and kinesiotaping facilitation technique is applied origin to insertion of non-dominant biceps brachii muscle before 24 hours the experiment.
Study NCT04070677 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ziverel
Description: Patients in treatments with radiotherapy alone (RT) or radiochemotherapy (RT-CH) with acute radiation-induced esophagitis grade 2 or superior according to the most recent CTCAE will received support treatment with ZIVEREL®
Study NCT01628627 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Frequency Modulated Neural Stimulation (FREMS) (Aptiva)
Description: FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly \~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
Study NCT01628627 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham treatment (Aptiva)
Description: The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
Study NCT01302938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolterodine ER
Description: One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
Study NCT01302938 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
Study NCT03380663 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Conditioning (RIC)
Description: Remote Ischemic Conditioning (RIC) is a new treatment modality to attenuate reperfusion injury. Organ protection by RIC can be achieved simply by inducing 3 or 4 five-minute cycles of limb ischemia and reperfusion using a tourniquet or simple blood pressure cuff Ischemic resistance exercise training conducted as low-intensity blood flow restricted resistance exercise (BFRE), with a low occlusion pressure stimulus, which only compromises venous but not arterial blood flow. Much like RIC, BFRE is conducted as 3-5 cycles (sets of exercise) interspaced by short duration of recovery.~High intensity traditional resistance training (TRT) is performed by sets of 10-12 repetitions are performed in the knee extensor machine - load equaling 15RM and rest for 3 minutes).
Study NCT02294474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR342434
Description: SAR342434 100 U/mL (dose range of 1 Unit to 80 Units) self-administered by subcutaneous (SC) injection, immediately (within 5 -10 minutes) before meals intake. Dose adjusted to achieve 2 hour post prandial glucose (PPG) in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
Study NCT02294474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Humalog 100 U/ml (dose range of 1 unit to 60 units) self-administered by SC injection, immediately (within 5-10 minutes) before meals intake. Dose adjusted to achieve a 2 hour PPG in range of 6.7 to 8.9 mmol/L (120 to 160 mg/dL) while avoiding hypoglycemia.
Study NCT02294474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine HOE901
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study NCT02294474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine HOE901
Description: Insulin glargine 100 U/mL injected QD subcutaneously consistent with the local label. Doses adjusted to achieve glycemic target for fasting, preprandial plasma glucose (SMPG) between 4.4 to 7.2 mmol/L (80 to 130 mg/dL) without hypoglycemia.
Study NCT02140346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT02140346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV1729 matching placebo 28 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT04220671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: measles vaccine
Description: Measles vaccine, Edmonston-Zagreb strain, 0.5 ml administered as a subcutaneous injection
Study NCT04220671 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% NaCl
Study NCT03178513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home visit
Description: The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:~* Medical assessment~* Psychosocial assessment~* Medication reconciliation~* Follow-up of inpatient primary team's specific recommendations~* Follow-up, as needed, with primary care team or inpatient team
Study NCT03077620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant
Description: Participants will be given a sleep aid (10mg or 20mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
Study NCT03077620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
Study NCT03472300 — intervention group
Intervention type: OTHER
Intervention: Survey about knee pain and treatment
Description: All citizens are surveyed to describe the prevalence of knee pain in a danish community.
Study NCT00690196 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih
Description: Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up.
Study NCT00690196 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
Study NCT02324764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glidesheath Slender
Description: testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
Study NCT02324764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard 6- French radial sheath
Study NCT03229434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mountain hiking
Description: Compare arm description
Study NCT03229434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mountain hiking
Description: Compare arm description
Study NCT01278108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0778
Description: single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
Study NCT01278108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose, oral solution or capsule (matching corresponding study medication)
Study NCT01278108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0778
Description: multiple dose, capsule, 7 days
Study NCT01278108 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: multiple dose, capsule, 7 days
Study NCT02141958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
Study NCT02141958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A matching placebo will be used to keep the study double-blind.
Study NCT03101124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 25 mg/ml for wound surface moistening
Description: Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
Study NCT03101124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 5 mg/ml as bolus in wound cavity
Description: 200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
Study NCT03101124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injectable Solution
Description: 1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
Study NCT03780270 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride Varnish
Description: Fluor Protector S (Ivoclar, 7'700 ppm F-)
Study NCT03780270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluoride Varnish
Description: Fluor Protector S (Ivoclar, 7'700 ppm F-)
Study NCT03780270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Repair
Description: P11-4 (monomeric peptide) - for professional use
Study NCT03780270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curodont Protect
Description: Tooth gel (containing P11-4 assembled to a fibrillary matrix) - for home use (OTC)
Study NCT02468934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT02397265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-hormonal closed loop pump
Description: Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
Study NCT02397265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard opened loop pump
Description: Using a standard opened loop pump
Study NCT02397265 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Insulin closed loop
Description: Using a closed loop
Study NCT04922190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching
Description: Participants will receive up to 5 coaching sessions by a physical or occupational therapist. The intervention will focus on facilitating physical activity engagement and development of specific and measurable goals. The recommended program will be individualized to each participant but will primarily focus on increasing general physical activity (e.g. steps per day) as well as engagement in moderate intensity aerobic exercise a minimum of three times per week. At the follow up sessions the therapist will review progress with the current exercise plan and progress and discuss barriers and facilitators for exercise engagement. Participants will have the option to use a Fitbit or other device to monitor their heart rate and physical activity during the course of the intervention period.
Study NCT00997256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))
Description: 3 x 2 tablets / day over 3 days
Study NCT00997256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: film-coated sugar-pill
Description: 3 x 2 tablets / day over 3 days
Study NCT02884557 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: collection of gut biopsies collection of blood samples
Description: Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
Study NCT00850304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosar
Description: Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
Study NCT00850304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide
Description: Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
Study NCT02535130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure
Study NCT02535130 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amikacine nebulization
Study NCT02535130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacine nebulization
Study NCT02720744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT218
Study NCT02720744 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00201461 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARFlex septal closure system
Description: transcatheter placement of STARFlex device to close a patent foramen ovale
Study NCT00201461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best medical therapy
Description: aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
Study NCT05983003 — intervention group
Intervention type: PROCEDURE
Intervention: endoscopic sinus surgery
Description: Open the sinus ostium, improve anatomical issues and remove the diseased tissue.
Study NCT06115395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non- invasive ventilator
Description: Group 1 (hypoexemic patient who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
Study NCT06115395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiber-optic bronchoscopy
Description: Group 2 (hypoxemic patients who will undergo conventional bronchoscopy under conventional o2 therapy without NIV ) will be on conventional oxygen therapy half an hour prior and throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
Study NCT06115395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non- invasive ventilator
Description: Group 3 (non- hypoxemic patients who will undergo bronchoscopy under non- invasive ventilation{NIV} and conventional o2 therapy) will be on NIV throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
Study NCT06115395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fiber-optic bronchoscopy
Description: Group 4 (non- hypoxemic patients who will undergo conventional bronchoscopy without non- invasive ventilation{NIV) will be on conventional oxygen therapy throughout the bronchoscopic sampling and after the procedure until reach the baseline criteria
Study NCT03140332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
Description: To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
Study NCT00348790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vatalanib
Study NCT01775358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-5281 0.015 mg/kg
Study NCT01775358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-5281 0.05 mg/kg
Study NCT01775358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-5281 0.15 mg/kg
Study NCT00506753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI/CBT
Description: Motivational Interviewing followed by Cognitive Behavior Therapy
Study NCT00506753 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RT/SU
Description: Relaxation Training followed by Treatment as Usual
Study NCT01775358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.015 mg/kg
Study NCT01775358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.05mg/kg
Study NCT01775358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.15mg/kg
Study NCT03375671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketalar
Description: single administration of 5 mg/kg, IM
Study NCT03375671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: single administration of 5 mg, IM
Study NCT03375671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: single administration of 5 mg, IM
Study NCT01967706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mTHS
Description: Single use of Tobacco Heating System 2.2 Menthol (mTHS)
Study NCT01967706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mCC
Description: Single use of subject's own menthol cigarette (mCC)
Study NCT01967706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NRT
Description: Single administration of 2 mg gum (Nicorette® 2mg)
Study NCT04305249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-017
Description: Dosing will begin at 5 mg QD ATG-017 as starting dose. A treatment cycle will be 21 days for continuous dosing and 28 days for 7 days on/7 days off intermittent dosing of ATG-017 treatment.
Study NCT04305249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG-017+Nivolumab
Description: With the combination with nivolumab, a cycle of study treatment will be defined as 28 days. ATG-017 is planned initially to be continuously given 28 days in each cycle. ATG-017 dosing schedule in combination therapy will follow a similar dose escalation principle as with monotherapy but starting at 5 mg BID. Nivolumab will be specified dose on specified days.
Study NCT02089334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX-0201
Description: RX-0201 will be administered in a dose up to 250mg/m\^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.~In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles.
Study NCT04638881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: Magnesium infusion 50 mg/kg bolus over 15 minutes and 25 mg/kg/hr infusion, both administered intraoperatively under general anesthesia.